Toll-Like Receptor-Targeting Immunotherapy for Oral Cancer

Oral Science International

Volumn 1, Issue 1, 2004, Pages 1-15

  Okamoto, Masato ^a   Sato, Mitsunobu ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Anti cancer immunotherapy; Dendritic cells; Innate immunity; OK 432; Toll like receptor

Indexed keywords

EID: 79955633667     PISSN: 13488643     EISSN: None     Source Type: Journal    
DOI: 10.11277/osi.1.1     Document Type: Article

References (64)

1. Okamoto H., Shoin S., Koshimura S., and Shimizu R. : Studies on the anticancer and streptolysin S-forming abilities of hemolytic streptococci. Jpn J Microbiol 11 : 323-336, 1967.
2. Maehara Y., Okuyama T., Kakeji Y., Baba H., Furusawa M., and Sigimachi K. : Postoperative immunochemotherapy including streptococcal lysate OK-432 is effective for patients with gastric cancer and serosal invasion. Am J Surg 168 : 36-40, 1994.
3. Kitahara S., Ikeda M., Inoue T., Matsunaga T., Yamaguchi K., Takayama E., Healy G. B., and Tsukuda M. : Inhibition of head and neck metastatic and/or recurrent cancer by local administration of multi-cytokine inducer OK-432. J Laryngol Otol 110 : 449-453, 1996.
4. Sato M., Harada K., Yoshida H., Yura Y., Azuma M., Iga H., Bando T., Kawamata H., and Takegawa Y. : Therapy for oral squamous cell carcinoma by tegafur and streptococcal agent OK-432 in combination with radiotherapy: Association of the therapeutic effect with differentiation and apoptosis in the cancet cells. Apoptosis 2 : 227-238, 1997.
5. Okamoto M., Oshikawa T., Tano T., Ohe G., Furuichi S., Nishikawa H., Ahmed S. U., Akashi S., Miyake K., Takeuchi O., Akira S., Moriya Y., Matsubara S., Ryoma Y., Saito M., and Sato M. : Involvement of Toll-like receptor 4 signaling in interferon- γproduction and anti-tumor effect by a streptococcal agent OK-432. J Natl Cancer Inst 95 : 316-326, 2003.
6. Oshimi K., Kano S., Takaku F., and Okumura K. : Augmentation of mouse natural killer cell activity by a streptococcal preparation, OK-432. J Natl Cancer Inst 65 : 1265-1269, 1980.
7. Saito M., Ebina T., Koi M., Yamaguchi T., Kamade Y., and Ishida N. : Induction of interferon-g in mouse spleen cells by OK-432, a preparation of Streptococcus pyogenes. Cell Immunol 68 : 187-192, 1982.
8. Fujimoto T., Duda R. B., Azilvasi A., Chen X., Mai M., and O'Donnell M. A. : Streptococcal preparation OK-432 is a potent inducer of IL-12 and a T helper cell 1 dominant state. J Immunol 158 : 5619-5626, 1997.
9. + T cells. Cancer Immunol Immunother 46 : 128-136, 1998.
10. Sato M., Yoshida H., Yanagawa T., Yura Y., Urata M., Atsumi M., and Takegawa Y. : Effect of intradermal administration of streptococcal preparation OK-432 on interferon and natural killer cell activities in patients with oral cancer. Int J Oral Surg 13 : 7-15, 1984.
11. Okamoto M., Furuichi S., O-he G., Nishilawa H., Tano T., Yoshida H., and Sato M. : Activation of human dendritic cells by an effective component of OK-432, a streptococcal agent, mediated by Toll-like receptor 4. J Jpn Stomatol Soc 52 : 51-62, 2003.
12. Nakahara S., Tsunoda T., Baba T., Asabe S., and Tahara H. : Dendritic cells stimulated with a bacterial product, OK-432, efficiently induce cytotoxic T lymphocytes specific to tumor rejection peptide. Cancer Res 63 : 4112-4118, 2003.
13. Itoh T., Ueda Y., Okugawa K., Fujiwara H., Fuji N., Yamashita T., Fujiki H., Harada S., Yoshimura T., and Yamagishi H. : Streptococcal preparation OK432 promotes functional maturation of human monocytederived dendritic cells. Cancer Immunol Immunother 52 : 207-214, 2003.
14. Kuroki H., Morisaki T., Matsumoto K., Onishi H., Baba E., Tanaka M., and Katano M. : Streptococcal preparation OK-432: a new maturation factor of monocyte-derived dendritic cellsfor clinical use. Cancer Immunol. Immunother 52 : 561-568, 2003.
15. Okamoto M., Kaji R., Kasetani H., Yoshida H., Moriya Y., Saito M., and Sato M. : Purification and characterization of interferon- γ-inducing molecule of OK-432, a penicillinkilled streptococcal preparation, by monoclonal antibody neutralizing interferon-γ -inducing activity of OK-432. J Immunother 13 : 232-242, 1993.
16. Medzhitov R., Preston-Hurlburt P., and Janeway C. A. Jr. : A human homolog of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388 : 394-397, 1997.
17. Akira S., Takeda K., and Kaisho T. : Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2: 675-680, 2001.
18. Azuma I., and Seya T. : Development of immunoadjuvants for immunotherapy of cancer. Int Immunopharmacol 1: 1249-1259, 2001.
19. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., Matsumoto M., Hoshino K., Wagner H., Takeda K., and Akira S. : A Toll-like recepter recognizes bacterial DNA. Nature 408 : 740-745, 2000.
20. Okamoto M., Oshikawa T., Ohe G., Nishikawa H., Furuichi S., Tano T., Moriya Y., Saito M., and Sato M. : Severe impairment of anti-cancer Effect of lipoteichoic acid-related molecule isolated from a penicillin-killed Streptococcus pyogenes in toll-like receptor 4-deficient mice. Int Immunopharmacol 1 : 1789-1795, 2001.
21. Fischer W. Bacterial phospholipids and lipoteichoic acids. Handbook of Lipid Reserch, Vol. 6 Glycolipids, phosphoglycolipids, and sulfoglycolipids (Fates K (ed)) Plenum Press, New York, 1990, pp. 123-234.
22. Tsutsui O., Kokeguchi S., Matsumura T., and Kato K. : Relationship of the chemical structure and immunobiological activities of lipoteichoic acid from Streptococcus faecalis (Enterococcus hirae) ATCC 9790. FEMS Microbiol Immunol 76 : 211-218, 1991.
23. Fischer W., Markwitz S., and Labischinski H. : Smallangle X-ray scattering analysis of pneumococcal lipoteichoic acid phase structure. Eur J Biochem 244 : 913-917, 1977.
24. Gorelik L., Prokhorova A., and Mokyr M. B. : Low-dose melpharan-induced shift in the production of a Th2-type cytokine to a Th1-type cytokine in mine bearing a large MOPC-315 tumor. Cancer Immunol Immunother 39 : 117-126, 1994.
25. Takeuchi T., Ueki T., Sasaki Y., Kajiwara T., Li B., Moriyama L., and Kawabe K. : Th2-like response and antitumor effect of anti-interleukin-4 mAb in mice bearing renal cell carcinoma. Cancer Immunol Immunother 43 : 375-381, 1997.
26. Asselin-Paturel C., Echchakir H., Carayol G., Gay F., Opolon P., Grunenwald D., Chouaib S., and Mami-Chouaib F. : Quantitative analysis of Th1, Th2 and TGFbetal cytokine expression in tumor, TIL and PBL of nonsmall cell lung cancer patients. Int J Cancer 77 : 7-12, 1998.
27. Okamoto M., Gohda H., Ohe G., Yoshida H., Matsuno T., Saito M., and Sato M. : Cytokine-inducing activity and anti-tumor effect of liposome-incorporated interferon- γinducing molecule derived from OK-432, a streptococcal preparation. J. Immunother 23 : 94-103, 2000.
28. Okamoto M., Ohe G., Oshikawa T., Nishikawa H., Furuichi S., Yoshida H., Matsuno T., Saito M., and Sato M. : Induction of Th11-type cytokines by lipoteichoic acidrelated preparation isolated from OK-432, a penicillinkilled streptococcal agent. Immunopharmacol 49 : 363-376, 2000.
29. Okamoto M., Oshikawa T., Ohe G., Furuichi S., Nishikawa H., Tano T., Bando T., Yoshida H., Matsubara S., Matsuno T., Saito M., and Sato M. : Comparison of cytokine-inducing activity in a lipoteichoic acid-related molecule isolated from a penicillin-killed group A Streptococcus and untreated bacteria. Int Immunopharmacol 1 : 1957-1968, 2001.
30. Oshikawa T., Okamoto M., Ohe G., Furuichi S., Nishikawa H., Ahmed S. U., Yoshida H., Moriya Y., Matsubara S., Ryoma Y., Saito M., and Sato M.: Isolation of a Th1-inducing molecule from OK-432, a streptococcal preparation, by a monoclonal antibody TS -2 that neutralizes the interferon- γ-inducing activity of OK-432 : Comparison of the enhancement of anti-tumor immunity between the TS-2-binding and TS-2-unbinding fraction. Int Immunopharmacol 3 : 643-655, 2003.
31. Okamoto M., Ohe G., Oshikawa T., Furuichi S., Nishikawa H., Tano T., Ahmed S. U., Yoshida H., Moriya Y., Saito M., and Sato M. : Enhancement of anti-cancer immunity by a lipoteichoic-acid-related molecule isolated from a penicillin-killed group A Streptococcus. Cancer Immunol Immunother 50 : 408-416, 2001.
32. Okamoto M., Ohe G., Furuichi S., Nishikawa H., Oshikawa T., Tano T., Ahmed S. U., Yoshida H., Moriya Y., Matsubara S., Ryoma Y., Saito M., and Sato M.: Enhancement of anti-tumor immunity by lipoteichoic acidrelated molecule isolated from OK-432, a streptococcal agent, in athymic nude mice bearing human salivary adenocarcinoma : Role of natural killer cells. Anticancer Res 22 : 3229-3240, 2002.
33. Morisato D., and Anderson K. V. : The spaetzle gene encodes a component of the extracellular signaling pathway establishing the dorsal-ventral pattern of the Drosophila embryo. Cell 76 : 677-688, 1994.
34. Lemaitre B., Nicolas E., Michaut L., Reichhart J. M., and Hoffmann J. A. : The dorsoventral regulatory gene cassette spatzle/Toll/Cactus controls the potent antifungal response in drosophila adults. Cell 86 : 973-983, 1996.
35. Akira S. : Toll-like receptor signaling. J Biol Chem 278 : 38105-38108, 2003.
36. Barton G. M., and Medzhitov R. : Toll-like receptors and their ligands. Curr Top Microbiol Immunol 270 : 81-92, 2002.
37. Akira S., Yamamoto M., and Takeda K. : Role of adaptors in Toll-like receptor signaling. Biochem Soc Trans 31 : 637-642, 2003.
38. Azuma I., Kanetsuna F., Taniyama T., Yamamura Y., and Hori M. : Adjuvant activity of microbacterial fractions : I. Purification and in vivo adjuvant activity of cell wall skeletons of Mycobacterium bovis BCG, Nocardia asteroids 131 and Corynebacterium diphtheriae PW8. Biken J 18:1-13, 1975.
39. Yamamura Y., Sakatani M., Ogura T., and Azuma I. : Adjuvant immunotherapy of lung cancer with BCG cellwall skeleton (BCG-CWS). Cancer 43 : 1314-1319, 1979.
40. Yasumoto K., Manabe H., Yanagawa E., Nagano N., Ueda H., Hirota N., Ohta M., Nomoto K., Azuma I., and Yamamura Y. : Nonspecific adjuvant immunotherapy on lung cancer with cell wall skeleton of Mycobacteria bovis, Bacillus Calmette-Guerin. Cancer Res 39 : 3262-3267, 1979.
41. Matsumoto M., Seya T., Kikkawa S., Tsuji S., Shida K., Nomura M., Kurita-Taniguchi M., Ohigashi H., Yokouchi H., Takami H., Hayashi A., Azuma I., Masaoka T., Kodama K., and Toyoshima K. : Interferon gammaproducing ability in blood lymphocytes of patients with lung cancer through activation of the innate immune system by BCG cell wall skeleton. Int Immunopharmacol 1 : 1559-1569, 2001.
42. Tsuji S., Matsumoto M., Takeuchi O., Akira S., Azuma I., Hayashi A., Toyoshima K., and Seya T. : Maturation of human dendritic cells by cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guéin: Involvement of Tolllike receptors. Infect Immun 68 : 6883-6890, 2000.
43. Tokunaga T., Yamamoto H., Shimada S., Abe H., Fukuda T., Fujisawa Y., Furutani Y., Tano O., Kataoka T., Sudo T., Makiguchi N., and Suganuma T. : Antitumor activity of Deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity. J Natl Cancer Inst 72: 955-962, 1984.
44. Krieg A. M., Yi A. K., Matson S., Waldschmidt T. J., Bishop G. A., Teasdale R., Koretzky G. A., and Klinman D. M. : CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374 : 546-549, 1995.
45. Krieg A. M. : CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 20 : 709-760, 2002.
46. Lipford G. B., Sparwasser T., Zimmermann S., Heeg K., Wagner H. : CpG-DNA-mediated transient lymphadenopathy is associated with a state of Th1 predisposition to antigen-driven responses. J Immunol 165 : 1228-1235, 2000.
47. Agrawal S., and Kandimalla E. R. : Medicinal chemistry and therapeutic potential of CpG DNA. Trend Mol Med 8 : 114-121, 2002.
48. Sato M., Kaji R., Urata M., Yoshida H., Yanagawa T., Miyamoto K., Azuma M., Furumoto N., and Saito M. : Monoclonal antibody to the streptococcal preparation OK-432: Tissue OK-432 localization and analysis of interaction between OK-432 and macrophages or NK cells in human salivary bland adenocarcinoma-bearing nude mice given OK-432. J Biol Response Modif 7 : 212-228, 1988.
49. Steinman R. M. : The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9 : 271-296, 1991.
50. Fong L., and Engleman E. G. : Dendritic cells in cancer immunotherapy. Annu Rev Immunol 18 : 245-273, 2000.
51. Okamoto M., Kasetani H., Kaji R., Goda H., Ohe G., Yoshida H., and Sato M. : Cis-diamminedichloroplatinum and 5-fluorouracil are potent inducers of the cytokines and natural killer cell activity in vivo and in vitro. Cancer Immunol Immunother 47 : 233-239, 1998.
52. Okamoto M., Ohe G., Oshikawa T., Nishikawa H., Furuichi S., Yoshida H., and Sato M. : Induction of cytokines and killer cell activities by cisplatin and 5fluorouracil in head and neck cancer patients. Anti- Cancer Drugs 11 : 165-173, 2000.
53. Okamoto M., Furuichi S., Tano T., Yoshida H., and Sato M. : Intratumoral administration of dendritic cells in combination with TS-1, an oral fluoropyrimidine anticancer drug, and OK-432, a streptococcal agent. J Jpn Stomatol Soc 53(1) : 14-21, 2004.
54. Trevani A. S., Chorny A., Salamone G., Vermeulen M., Gamberale R., Schettini J., Raiden S., and Geffner J. : Bacterial DNA activates human neutrophils by a CpGindependent pathway. Eur J Immunol 33 : 3164-3174, 2003.
55. Saikh K., Lee J. S., Kissner T. L., Dyas B., and Ulrich R. G. : Toll-like receptor and cytokine expression patterns of CD56 + T cells are similar to natural killer cells in response to infection with Venezuelan equine encephalitis virus replicons. J Infect Des 188 : 1562-1570, 2003.
56. Agrawal S., Agrawal A., Doughty B., Gerwitz A., Blenis J., Van Dyke T., and Pulendran B. : Different Toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitigen-activated protein kinase and c-Fos. J Immunol 171 : 4984-4989, 2003.
57. Takeuchi O., Hoshino K., Kawai T., Sanjo H., Takada H., Ogawa T., Takeda K., and Akira S. : Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity 11 : 443-451, 2001.
58. Yang S., Tamai R., Akashi S., Takeuchi O., Akira S., Sugawara S., and Takada H. : Synergistic effect of muramyldipeptide with lipopolysaccharide or lipoteichoic acid to induce inflammatory cytokines in human monocytic cells in culture. Infect Immun 69 : 2045-2053, 2001.
59. Schwandner R., Dziarski R., Wesche H., Rothe M., and Kirschning C. : Peptidoglycan and lipoteichoic acidinduced cell activation is mediated by Toll-like receptor 2. J Biol Chem 274 : 17406-17409, 1999.
60. Morath S., Geyer A., and Hartung T. : Structure-function relationship of cytokine induction by lipoteichoic acid from Staphylococcus aureus. J Exp Med 193 : 393-397, 2001.
61. Morath S., Stadelmaier A., Geyer A., Schmidt R. R., and Hartung T. : Synthetic lipoteichoic acid from Staphylococcus aureus is a potent stimulus of cytokine release. J Exp Med 195 : 1635-1640, 2002.
62. Michelsen K. S., Aicher A., Mohaupt M., Hartung T., Dimmeler S., Kirschning C. J., and Schumann R. R. : The role of Toll-like receptors3 TLRs) in bacteria-induced maturation of murine dendritic cells3 DCs). Peptydoglycan and lipoteichoic acid are inducers of DC maturation and require TLR2. J Biol Chem 276 : 25680-25686, 2001.
63. Takada H., Kawabata Y., Arakaki R., Kusumoto S., Fukase K., Suda Y., Yoshimura T., Kokeguch S., Kato K., Komuro T., Tanaka N., Saito M., Yoshida T., Sato M., and Kotani, S. : Molecular and structural requirements of a lipoteichoic acid from Enterococcus hirae ATCC 9790 for cytokine-inducing, antitumor, and antigenic activities. Infect Immun 63 : 57-65, 1995.
64. Netea M. G., van Deuren M., Kullberg B. J., Cavaillon J.-M., and van der Meer J. W. M. : Does the shape of lipid A determine the interaction of LPS with Toll-like receptors ? Trend Immunol 23 : 135-139, 2002.